Cutaneous T-Cell Lymphoma Clinical Trials

A listing of Cutaneous T-Cell Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 46 clinical trials
Featured trial
A Prospective, Observational, US-based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma and Treated With Valchlor®

A Prospective, Observational, US-based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma and

  • 607 views
  • 23 Nov, 2020
  • 1 location
Anti-CCR4 Monoclonal Antibody (Mogamulizumab) and Total Skin Electron Beam Therapy (TSEB) in Patients With Stage IB-IIB Cutaneous T-Cell Lymphoma (MOGAT)

Cutaneous T-Cell Lymphoma (CTCL) has a chronic, relapsing course with patients undergoing multiple, consecutive therapies. Treatment aims at the clearance of skin disease, minimization of

  • 0 views
  • 07 Apr, 2023
  • 6 locations
BI-1808 as a Single Agent and With Pembrolizumab in Treatment of Advanced Malignancies(Keynote-D20)

iRECIST can be applied for efficacy assessment) and subjects with cutaneous T-cell lymphoma (CTCL), specifically Sézary Syndrome (SS) and mycosis fungoides (MF). The study will consist of 2 phases

  • 38 views
  • 07 Oct, 2022
  • 5 locations
Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) (MNA-D)

-specific immunity. The purpose of this study is to test a new method of experimental treatment for CTCL, using small adhesive-like patches (a micro-needle applicator or MNA for short), which have

doxorubicin
topical steroids
antineoplastic agents
puva
cutaneous t-cell lymphoma
  • 37 views
  • 15 Jun, 2022
  • 1 location
Mogamulizumab Q4week Dosing in Participants With R/R CTCL

/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years

  • 0 views
  • 04 Oct, 2022
  • 5 locations
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

This is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of …

fungal infection
t-cell lymphoma
cutaneous t-cell lymphoma
peripheral t-cell lymphoma
measurable disease
  • 81 views
  • 04 Oct, 2022
  • 2 locations
Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma

This phase II trial studies the effect of extracorporeal photopheresis (ECP) and mogamulizumab in treating patients with erythrodermic cutaneous T cell lymphoma (CTCL), a type of skin lymphoma

metastases
extracorporeal photopheresis
skin biopsy
measurable disease
microscopic examination
  • 0 views
  • 09 Apr, 2023
  • 1 location
Phase 1B, Pilot Study to Assess the Pharmacodynamics, Pharmacokinetics, Safety, Activity of Pembrolizumab Administered Intra-lymphatically Using the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T- Cell Lymphoma (CTCL)

In this pilot study, pembrolizumab will be administered via DoseConnect in patient with relapsed or refractory cutaneous T-cell lymphoma to assess through pharmacodynamic assessment in the tumor

brentuximab
t-cell lymphoma
lymphoma
mycosis
cutaneous t-cell lymphoma
  • 0 views
  • 22 Oct, 2022
  • 1 location
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

The body has different ways of fighting infection and disease. No single way is perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body from disease caused by bacteria or toxic substances. Antibodies work by …

treatment regimen
brentuximab
diffuse large b-cell lymphoma
hodgkin's disease
autologous transplant
  • 324 views
  • 10 Sep, 2023
  • 1 location
A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma

This is a first in human, open-label, dose escalation and expansion Phase 1 study of SIM1811-03 in adult patients with advanced solid tumors and cutaneous T-cell lymphoma. SIM1811-03 is a first

monoclonal antibodies
metastases
cutaneous t-cell lymphoma
measurable disease
lymphoma
  • 0 views
  • 24 Oct, 2022
  • 1 location